A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
== Personal life == John Knox celebrated 60 years of marriage to his wife Josephine in March 2017. He died on 15 October 2018 in Edinburgh, aged 90. He is survived by his wife, four sons, 12 grandchildren, and 4 great-grandchildren.
The peak of these incidents occurred in 1980, with new recruit Phil Carman making headlines for head-butting an umpire. The tribunal suspended him for sixteen weeks, and although most people thought this was a fair (or even lenient) sentence, he took his case to the Supreme Court of Victoria, gathering even more unwanted publicity for the club. Despite this, the club had recruited many talented young players in the late 1970s who emerged as club greats. Three of those young players were Simon Madden, Tim Watson and Paul Van Der Haar. Terry Daniher and his brother Neale came via a trade with South Melbourne, and Roger Merrett joined soon afterwards to form the nucleus of what would become the formidable Essendon sides of the 1980s. This raw but talented group of youngsters took Essendon to an elimination final in 1979 under Barry Davis but were again thrashed in an Elimination Final, this time at the hands of Fitzroy. Davis resigned at the end of the 1980 season after missing out on a finals appearance. One of the few highlights for Essendon supporters during this time was when Graham Moss won the 1976 Brownlow Medal; he was the only Bomber to do so in a four-decade span from 1953 to 1993. Even that was bittersweet, as he quit VFL football to move back to his native Western Australia, where Moss finished out his career as a player and coach at Claremont Football Club. In many ways, Moss's career reflects Essendon's mixed fortunes during the decade.
Amazon, America's second largest employer, eliminated cannabis testing in job pre-screening, where not required by government regulations, stating, "Pre-employment marijuana testing has disproportionately affected communities of color by stalling job placement." In a survey of 45,000 companies worldwide, 9% reported the elimination of testing to improve hiring. In 2022, thousands of US truck drivers were taken off the road after testing positive for cannabis, contributing to a severe driver shortage; a conflict between the majority of states with some form of cannabis legalization, and the federal Department of Transportation's zero-tolerance cannabis policy, even for medical use, is cited as a problem.
Sources: en.wikipedia.org
Register and use state prescription drug monitoring programs Enhance education and training Support comprehensive treatment for pain and substance use disorders Help end stigma Co-prescribe naloxone to patients at risk of overdose Encourage safe storage and disposal of opioids and all medications. The Opioid Task Force 2018 Progress Report states that between 2013 and 2017 opioid prescriptions have decreased by 22.2%, which includes a 9% decrease from 2016 to 2017 alone. The AMA Opioid Task Force also reports a 389% increase in physician participation in PDMPs. Further, physicians are encouraged to co-prescribe naloxone to those at risk of overdose. In 2017 alone, weekly filled naloxone prescriptions have more than doubled from 3,500 to 8,000 and more than 50,000 physicians were certified in 2017 to provide in-office buprenorphine. Patrice A. Harris, chair of the AMA Opioid Task Force, urges increased participation by physicians, saying "what is needed now is a concerted effort to greatly expand access to high quality care for pain and for substance use disorders. Unless and until we do that, this epidemic will not end."
The hair perforation test, also known as an in vitro hair perforation test, is a laboratory test used to help distinguish the isolates of dermatophytes, such as Trichophyton mentagrophytes and its variants. The test is performed by placing an organism into a Petri dish containing water, yeast extract, and hair. After incubation for 4 week, they are examined under microscopy T.mentagrophyte would have produced erosions on the Hair while T. Rubrum will not produce any change. Hence they are used to differtiate dermatophytes. The Mayo Clinic's mycology laboratory has identified five common dermatophytes; Microsporum gypseum, Microsporum canis, Trichophyton rubrum, Trichophyton mentagrophytes, and Trichophyton tonsurans.
==== Aerosol mass spectrometer ==== The Aerodyne AMS provides real-time aerosol mass spectrometry analysis of size-resolved mass concentration of non-refractory components (Ex. organics, sulfate, nitrate, and ammonium). The term non-refractory is assigned to species that evaporate rapidly at 600 °C under vacuum conditions (e.g. organic matter, NH4NO3 and (NH4)2SO4. The schematic of a typical AMS is shown in the figure to the right. The Aerodyne AMS is made up of three sections; The aerosol inlet, the particle sizing chamber, and the particle detection chamber. The aerosol inlet has a flow limiting orifice entrance that is around 100 um in diameter. Once in the chamber the sample goes through aerodynamic focusing lens system, which consist of several orifice lenses that are mount in sequence of decreasing inner diameter. The lens focuses the particles into a narrow particle beam. The beam now travels through the particle sizing chamber, where the particle aerodynamic diameter is measured. The particle sizing chamber is made up of a flight tube maintained at (~ 10−5 torr). The entrance of the flight tube is a mechanical chopper that's used to modulate the particle beam; then using both the fixed length of the tube and the time-resolved detection of the arrival at the end, the particles' velocities can be determined. Using the velocity, the particle's diameter is obtained. As the particle beam exits the flight tube, it enters the particle composition detection chamber. In this section, the particles collide with a heated tungsten element (~600 °C).
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.